Quizartinib dihydrochlorideProduct ingredient for Quizartinib
- Name
- Quizartinib dihydrochloride
- Drug Entry
- Quizartinib
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind.1 Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.4 FLT3-ITD mutation is present in 75% of FLT3-mutated AML, leading to constitutively active FLT3 and thus poorer overall survival and higher risk of relapse.2 Multiple clinical trials have demonstrated quizartinib's efficacy in relapsed/refractory FLT3-ITD mutant AML.3 Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize quizartinib's addition to AML standard of care.1
Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo.6 The FDA approval was based on positive results from the QuANTUM-First trial for FLT3-ITD positive AML, where quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death.6
- Accession Number
- DBSALT003051
- Structure
- Synonyms
- Quizartinib dihydrochloride
- UNII
- WK7Q6ZIZ10
- CAS Number
- 1132827-21-4
- Weight
- Average: 633.59
Monoisotopic: 632.1739302 - Chemical Formula
- C29H34Cl2N6O4S
- InChI Key
- DHYPGRVMIOATAE-UHFFFAOYSA-N
- InChI
- InChI=1S/C29H32N6O4S.2ClH/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34;;/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);2*1H
- IUPAC Name
- 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(8),3,5,9,11-pentaen-4-yl}phenyl)urea dihydrochloride
- SMILES
- Cl.Cl.CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
- External Links
- ChemSpider
- 25069710
- ChEMBL
- CHEMBL2105709
- Predicted Properties
Property Value Source Water Solubility 0.0509 mg/mL ALOGPS logP 5.13 ALOGPS logP 4.99 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 8.28 Chemaxon pKa (Strongest Basic) 6.61 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 106.16 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 168.24 m3·mol-1 Chemaxon Polarizability 63.57 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon